Abstract 354P
Background
Colorectal cancer (CRC) presents among leading causes of death and oligometastases presents a dilemma in treatment options. If treated, CRC with oligometastases can present improved survival. Our study aims to evaluate predictive factors associated with survival when treated with stereotactic body radiation therapy (SBRT).
Methods
A total of 125 metastases in 50 patients were treated with SBRT. Oligometastases was defined as up to 5 lesions in lung in proven primary histopathology of CRC. Survival outcomes in terms of local control (LC), progression free survival (PFS), and overall survival (OS) were assessed along with association of various predictive factors associated with survival outcomes.
Results
Among the 50 patients, Lung was the most common site of metastases (52.5%), followed by liver (34%). Thirty patients had received prior systemic therapy in form of chemotherapy. Median follow-up time was 24 months (6-84 months). The LC rates at 1, 3 and 5 years were 96%, 72% and 69%, respectively. The first site of failure was local only in 20%, distant only in 34%, and local and distant in 16% of the patients. Median PFS was 9.8 months. The overall survival at 1, 3 and 5 years was 87.2%, 62.3%, and 41.4%, respectively. On assessment of predictive factors, metastases more than 3 cm (p =0.012), presence of non-lung metastases (p < 0.001) and progression of treated metastases (p = 0.021) predicted for worse overall survival.Multiple lung metastases and synchronous oligometastatic disease were significantly associated with worse PFS and worse metastases-free survival. On toxicity assessment, no Grade 3 toxicities were found in the cohort.
Conclusions
Stereotactic body radiation therapy presents longer survival in oligometastases in CRC and is a proven treatment modality. Treatment and control of oligometastases predicts for improved overall survival. Further prospective cohorts would better evaluate effective fractionation for patients with oligometastatic CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract